Weight loss can be a challenging journey for many people, and some turn to weight-loss medications to help them shed those extra pounds. One popular class of drugs, known as glucagonlike peptide 1 (GLP-1) receptor agonists, has been shown to be effective in promoting weight loss and improving heart health in many individuals. However, a recent study published in the BMJ has shed light on what happens to individuals’ health after they stop taking these medications.
The study found that individuals who discontinued weight-loss drugs, including GLP-1 medications, experienced a rapid regain of weight and a reversal of the heart health benefits they had initially seen. In fact, those who stopped taking weight-loss medications regained weight four times faster than those who stopped dieting or exercising to lose weight.
Lead author of the study, Sam West, highlighted the alarming rate at which individuals regained weight after stopping medication. The study evaluated various weight-loss drugs, including older-generation GLP-1 medications, orlistat, and the combination of phentermine and topiramate, comparing them to behavioral weight-loss interventions such as dieting and exercise.
The results showed that individuals who discontinued weight-loss drugs regained approximately a pound per month on average and experienced a reversal in their cardiometabolic markers. This led to weight returning to its pre-treatment level within 1.7 years and heart health markers returning to their pre-treatment state within 1.4 years.
The findings underscore the challenges individuals face in maintaining weight loss after stopping medication. While weight-loss drugs may lead to rapid results, quitting them can result in even faster weight regain, with potential negative impacts on overall health.
Experts suggest that a potential strategy for individuals coming off weight-loss medications could be to transition into a behavioral program, such as a diet or exercise regimen. However, further research is needed to fully understand the implications of stopping weight-loss medications on weight and health outcomes.
Overall, the study serves as a reminder of the complex nature of treating obesity and the importance of long-term support for individuals undergoing weight-loss interventions. It also highlights the need for continued research and support for individuals struggling with weight management.
As the conversation around weight loss and medication continues, it is crucial to consider the long-term effects of these interventions and the importance of comprehensive support for individuals on their weight-loss journey.
